Police & Firemen s Retirement System of New Jersey Purchases 7,165 Shares of Alumis Inc. $ALMS

Police & Firemen s Retirement System of New Jersey raised its position in Alumis Inc. (NASDAQ:ALMS) by 199.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,753 shares of the company’s stock after acquiring an additional 7,165 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Alumis were worth $32,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kera Capital Partners Inc. purchased a new stake in shares of Alumis during the 2nd quarter valued at $32,000. ProShare Advisors LLC acquired a new position in Alumis during the 2nd quarter valued at about $40,000. Corebridge Financial Inc. raised its stake in Alumis by 53.0% in the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock valued at $65,000 after buying an additional 3,693 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after buying an additional 4,926 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after acquiring an additional 2,949 shares in the last quarter.

Alumis Trading Down 4.2%

Shares of NASDAQ ALMS opened at $7.35 on Tuesday. The company has a 50 day simple moving average of $5.11 and a two-hundred day simple moving average of $4.37. The stock has a market cap of $767.27 million, a price-to-earnings ratio of -1.81 and a beta of -1.91. Alumis Inc. has a 12 month low of $2.76 and a 12 month high of $10.49.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $3.14 million. Analysts forecast that Alumis Inc. will post -8.51 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Foresite Capital Management Vi bought 200,000 shares of the stock in a transaction dated Monday, November 17th. The shares were purchased at an average price of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the purchase, the insider directly owned 2,234,129 shares of the company’s stock, valued at $12,488,781.11. This represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Foresite Labs, Llc bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were bought at an average cost of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the acquisition, the insider owned 2,234,129 shares of the company’s stock, valued at $12,488,781.11. This trade represents a 9.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 2,340,471 shares of company stock worth $14,478,507. Corporate insiders own 40.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Morgan Stanley cut their price objective on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Alumis in a research note on Tuesday, November 25th. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Alumis in a research report on Thursday, August 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.20.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.